Sun Pharmaceutical Industries’ subsidiary has entered into exclusive licensing and supply agreements with Rockwell Medical Inc. to commercialize Rockwell’s Triferic, a proprietary iron replacement and haemoglobin maintenance drug, for treating anaemia in hemodialysis patients in India. Triferic is approved in USA.

Sun Pharma will be the exclusive development and commercialization partner for Triferic during the term of the agreement. In consideration for the license, Rockwell will be eligible for upfront and milestone payments as well as a royalty on sales. Financial terms were not disclosed.

Kirti Ganorkar, chief executive officer of India business, Sun Pharma, said, “We are excited to build a partnership with Rockwell who has developed an innovative product, Triferic for haemodialysis patients. Triferic is an innovative anaemia therapy for patients who are undergoing haemodialysis and offers a unique treatment option. Triferic will help Sun Pharma expand its portfolio in its core therapy areas.”